{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:38:55Z","timestamp":1793421535198,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11892-022-01491-y","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T01:02:47Z","timestamp":1662080567000},"page":"525-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review"],"prefix":"10.1007","volume":"22","author":[{"given":"Jason A.","family":"Zehden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier M.","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashvini","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5194-5256","authenticated-orcid":false,"given":"Alice Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"1491_CR1","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"1491_CR2","doi-asserted-by":"publisher","first-page":"e022188","DOI":"10.1136\/bmjopen-2018-022188","volume":"9","author":"R Cheloni","year":"2019","unstructured":"Cheloni R, Gandolfi SA, Signorelli C, Odone A. Global prevalence of diabetic retinopathy: protocol for a systematic review and meta-analysis. BMJ Open. 2019;9(3):e022188.","journal-title":"BMJ Open"},{"issue":"3","key":"1491_CR3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JWY Yau","year":"2012","unstructured":"Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556\u201364.","journal-title":"Diabetes Care"},{"issue":"6","key":"1491_CR4","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","volume":"32","author":"S Fogli","year":"2018","unstructured":"Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye. 2018;32(6):1010\u201320.","journal-title":"Eye"},{"issue":"4","key":"1491_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/eye.2014.329","volume":"29","author":"SJ Park","year":"2015","unstructured":"Park SJ, Oh J, Kim Y-K, Park JH, Park JY, Hong HK, et al. Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model. Eye. 2015;29(4):561\u20138.","journal-title":"Eye"},{"issue":"7","key":"1491_CR6","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1089\/jop.2013.0009","volume":"29","author":"J Ahn","year":"2013","unstructured":"Ahn J, Kim H, Woo SJ, Park JH, Park S, Hwang DJ, et al. Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes. J Ocul Pharmacol Ther. 2013;29(7):612\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"1491_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1167\/iovs.13-13054","volume":"55","author":"SJ Ahn","year":"2014","unstructured":"Ahn SJ, Ahn J, Park S, Kim H, Hwang DJ, Park JH, et al. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2014;55(1):567\u201373.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"1491_CR8","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"\u2022 Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina Phila Pa. 2017;37(10):1847. (This article discusses the pharmacokinetics of anti-VEGF agents.)","journal-title":"Retina Phila Pa"},{"key":"1491_CR9","doi-asserted-by":"crossref","unstructured":"Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981;88(7):583\u2013600.","DOI":"10.1016\/S0161-6420(81)34978-1"},{"issue":"12","key":"1491_CR10","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","volume":"103","author":"Photocoagulation for Diabetic Macular Edema","year":"1985","unstructured":"Photocoagulation for Diabetic Macular Edema. Early Treatment Diabetic Retinopathy Study Report Number 1 Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol. 1985;103(12):1796\u2013806.","journal-title":"Arch Ophthalmol"},{"issue":"20","key":"1491_CR11","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2015.15217","volume":"314","author":"JG Gross","year":"2015","unstructured":"Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137\u201346.","journal-title":"JAMA"},{"issue":"7","key":"1491_CR12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jamaophthalmol.2021.0606","volume":"139","author":"RK Maturi","year":"2021","unstructured":"Maturi RK, Glassman AR, Josic K, Antoszyk AN, Blodi BA, Jampol LM, et al. Effect of intravitreous anti\u2013vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol w randomized clinical trial. JAMA Ophthalmol. 2021;139(7):701\u201312.","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"1491_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaophthalmol.2021.2809","volume":"139","author":"DM Brown","year":"2021","unstructured":"Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, et al. Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy. JAMA Ophthalmol. 2021;139(9):1\u201310.","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"1491_CR14","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier JS, Korobelnik J-F, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2016;123(11):2376\u201385.","journal-title":"Ophthalmology"},{"issue":"1","key":"1491_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ophtha.2017.07.005","volume":"125","author":"V Daien","year":"2018","unstructured":"Daien V, Nguyen V, Essex RW, Morlet N, Barthelmes D, Gillies MC, et al. Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration. Ophthalmology. 2018;125(1):66\u201374.","journal-title":"Ophthalmology"},{"issue":"10","key":"1491_CR16","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","volume":"120","author":"DM Brown","year":"2013","unstructured":"Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013\u201322.","journal-title":"Ophthalmology"},{"issue":"4","key":"1491_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1600-0420.2007.01067.x","volume":"86","author":"C Shima","year":"2008","unstructured":"Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol (Copenh). 2008;86(4):372\u20136.","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"4","key":"1491_CR18","doi-asserted-by":"publisher","first-page":"e527","DOI":"10.1111\/aos.14345","volume":"98","author":"M Haruta","year":"2020","unstructured":"Haruta M, Ishibashi K, Ishibashi Y, Dake S, Sasaki K, Noda R, et al. Multiple retinal vein thromboses after intravitreal aflibercept injections for age-related macular degeneration. Acta Ophthalmol (Copenh). 2020;98(4):e527\u20138.","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"9900","key":"1491_CR19","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. The Lancet. 2013;382(9900):1258\u201367.","journal-title":"The Lancet"},{"issue":"7","key":"1491_CR20","doi-asserted-by":"publisher","first-page":"e101145","DOI":"10.1371\/journal.pone.0101145","volume":"9","author":"LI Faruque","year":"2014","unstructured":"Faruque LI, Lin M, Battistella M, Wiebe N, Reiman T, Hemmelgarn B, et al. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS ONE. 2014;9(7):e101145.","journal-title":"PLoS ONE"},{"issue":"3","key":"1491_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/IAE.0b013e31819a5f98","volume":"29","author":"ID Ladas","year":"2009","unstructured":"Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina. 2009;29(3):313\u20138.","journal-title":"Retina"},{"issue":"1","key":"1491_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","volume":"246","author":"L Wu","year":"2008","unstructured":"Wu L, Mart\u00ednez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin\u00ae): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246(1):81\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"1491_CR23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789\u2013801.","journal-title":"Ophthalmology"},{"issue":"13","key":"1491_CR24","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"The Diabetic Retinopathy Clinical Research Network","year":"2015","unstructured":"The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193\u2013203.","journal-title":"N Engl J Med"},{"issue":"8","key":"1491_CR25","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1136\/bjophthalmol-2015-307707","volume":"100","author":"N Rayess","year":"2016","unstructured":"Rayess N, Rahimy E, Shah CP, Wolfe JD, Chen E, DeCroos FC, et al. Incidence and clinical features of post-injection endophthalmitis according to diagnosis. Br J Ophthalmol. 2016;100(8):1058\u201361.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1491_CR26","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/IAE.0b013e31820a67e4","volume":"31","author":"CA Mccannel","year":"2011","unstructured":"Mccannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti\u2013vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654\u201361.","journal-title":"Retina"},{"issue":"2","key":"1491_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jcjo.2017.07.027","volume":"53","author":"S Zafar","year":"2018","unstructured":"Zafar S, Hamid A, Bin Mahmood SU, Burq MA, Maqsood N. Incidence of endophthalmitis after intravitreal injections at a tertiary care hospital. Can J Ophthalmol. 2018;53(2):94\u20137.","journal-title":"Can J Ophthalmol"},{"issue":"2","key":"1491_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10792-016-0241-4","volume":"37","author":"Y Xu","year":"2017","unstructured":"Xu Y, Tan CS. Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol. 2017;37(2):325\u201332.","journal-title":"Int Ophthalmol"},{"issue":"10","key":"1491_CR29","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1097\/IAE.0b013e3181884fd2","volume":"28","author":"DR Fintak","year":"2008","unstructured":"Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina Phila Pa. 2008;28(10):1395\u20139.","journal-title":"Retina Phila Pa"},{"issue":"8","key":"1491_CR30","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ophtha.2018.01.022","volume":"125","author":"K Xu","year":"2018","unstructured":"\u2022\u2022 Xu K, Chin EK, Bennett SR, Williams DF, Ryan EH, Dev S, et al. Endophthalmitis after intravitreal injection of vascular endothelial growth factor inhibitors. Ophthalmology. 2018;125(8):1279\u201386. (This study is a recent retrospective chart review of patients that received intravitreal anti-VEGF injections and the incidence of endophthalmitis.)","journal-title":"Ophthalmology"},{"issue":"2","key":"1491_CR31","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1177\/1120672120902028","volume":"31","author":"S Torres-Costa","year":"2021","unstructured":"Torres-Costa S, Ramos D, Brand\u00e3o E, Carneiro \u00c2, Rosas V, Rocha-Sousa A, et al. Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis. Eur J Ophthalmol. 2021;31(2):600\u20136.","journal-title":"Eur J Ophthalmol"},{"issue":"7","key":"1491_CR32","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.ophtha.2012.01.016","volume":"119","author":"E Milder","year":"2012","unstructured":"Milder E, Vander J, Shah C, Garg S. Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology. 2012;119(7):1420\u20134.","journal-title":"Ophthalmology"},{"issue":"11","key":"1491_CR33","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/j.ophtha.2015.07.005","volume":"122","author":"BL VanderBeek","year":"2015","unstructured":"VanderBeek BL, Bonaffini SG, Ma L. The association between intravitreal steroids and post-injection endophthalmitis rates. Ophthalmology. 2015;122(11):2311-2315.e1.","journal-title":"Ophthalmology"},{"issue":"6","key":"1491_CR34","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Ophthalmology. 2016;123(6):1351\u20139.","journal-title":"Ophthalmology"},{"issue":"21","key":"1491_CR35","first-page":"00368","volume":"S0161\u20136420","author":"SN Patel","year":"2021","unstructured":"Writing committee for the Post-Injection Endophthalmitis Study Group, Patel SN, Tang PH, Storey PP, Wolfe JD, Fein J, et al. The influence of universal face mask use on endophthalmitis risk after intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 2021;S0161\u20136420(21):00368\u20137.","journal-title":"Ophthalmology"},{"issue":"3","key":"1491_CR36","first-page":"473","volume":"32","author":"RR Doshi","year":"2012","unstructured":"Doshi RR, Leng T, Fung AE. Reducing oral flora contamination of intravitreal injections with face mask or silence. Retina Phila Pa. 2012;32(3):473\u20136.","journal-title":"Retina Phila Pa"},{"issue":"12","key":"1491_CR37","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1001\/archophthalmol.2011.227","volume":"129","author":"JC Wen","year":"2011","unstructured":"Wen JC, McCannel CA, Mochon AB, Garner OB. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol. 2011;129(12):1551\u20134.","journal-title":"Arch Ophthalmol"},{"issue":"2018","key":"1491_CR38","first-page":"8567912","volume":"24","author":"PET Lau","year":"2018","unstructured":"Lau PET, Jenkins KS, Layton CJ. Current evidence for the prevention of endophthalmitis in anti-VEGF intravitreal injections. J Ophthalmol. 2018;24(2018):8567912.","journal-title":"J Ophthalmol"},{"issue":"10","key":"1491_CR39","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1001\/jamaophthalmol.2016.2741","volume":"134","author":"AR Bhavsar","year":"2016","unstructured":"Bhavsar AR, Glassman AR, Stockdale CR, Jampol LM. Diabetic retinopathy clinical research network. elimination of topical antibiotics for intravitreous injections and the importance of using povidone-iodine: update from the diabetic retinopathy clinical research network. JAMA Ophthalmol. 2016;134(10):1181\u20133.","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"1491_CR40","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.ophtha.2012.02.014","volume":"119","author":"CSY Cheung","year":"2012","unstructured":"Cheung CSY, Wong AWT, Lui A, Kertes PJ, Devenyi RG, Lam W-C. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119(8):1609\u201314.","journal-title":"Ophthalmology"},{"issue":"12","key":"1491_CR41","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/eye.2012.199","volume":"26","author":"DAM Lyall","year":"2012","unstructured":"Lyall DAM, Tey A, Foot B, Roxburgh STD, Virdi M, Robertson C, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye. 2012;26(12):1517\u201326.","journal-title":"Eye"},{"issue":"4","key":"1491_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000486145","volume":"239","author":"A Grzybowski","year":"2018","unstructured":"Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A, et al. 2018 Update on intravitreal injections: euretina expert consensus recommendations. Ophthalmologica. 2018;239(4):181\u201393.","journal-title":"Ophthalmologica"},{"issue":"3","key":"1491_CR43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/15569520903080511","volume":"28","author":"J Jiang","year":"2009","unstructured":"Jiang J, Wu M, Shen T. The toxic effect of different concentrations of povidone iodine on the rabbit\u2019s cornea. Cutan Ocul Toxicol. 2009;28(3):119\u201324.","journal-title":"Cutan Ocul Toxicol"},{"issue":"7","key":"1491_CR44","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/OPX.0000000000001091","volume":"94","author":"WH Ridder","year":"2017","unstructured":"Ridder WH, Oquindo C, Dhamdhere K, Burke J. Effect of povidone iodine 5% on the cornea, vision, and subjective comfort. Optom Vis Sci. 2017;94(7):732\u201341.","journal-title":"Optom Vis Sci"},{"issue":"8","key":"1491_CR45","first-page":"e1154","volume":"97","author":"TH Dohlman","year":"2019","unstructured":"Dohlman TH, Lertsuwanroj B, D\u2019Amico DJ, Ciralsky JB, Kiss S. Evaluation of signs and symptoms of ocular surface disease after intravitreal injection. Acta Ophthalmol 1755375X. 2019;97(8):e1154-6.","journal-title":"Acta Ophthalmol 1755375X"},{"issue":"4","key":"1491_CR46","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/15569527.2017.1291665","volume":"36","author":"H Saedon","year":"2017","unstructured":"Saedon H, Nosek J, Phillips J, Narendran N, Yang YC. Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injections. Cutan Ocul Toxicol. 2017;36(4):343\u20136.","journal-title":"Cutan Ocul Toxicol"},{"issue":"13","key":"1491_CR47","first-page":"3696","volume":"55","author":"V Srinagesh","year":"2014","unstructured":"Srinagesh V, Ellenberg D, Scharper PH, Etter J. Intravitreal dry eye study. Invest Ophthalmol Vis Sci. 2014;55(13):3696.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"1491_CR48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/ICO.0000000000002836","volume":"41","author":"OA Polat","year":"2022","unstructured":"Polat OA, \u015eener H, Erkili\u00e7 K. Corneal nerve fiber and sensitivity loss after repeated intravitreal Anti-VEGF Injections: an in vivo confocal microscopy study. Cornea. 2022;41(3):317\u201321.","journal-title":"Cornea"},{"key":"1491_CR49","doi-asserted-by":"crossref","unstructured":"uluta\u015f hafize g\u00f6kben. Effects of intravitreal injection on ocular surface and anterior segment parameters. Beyoglu Eye J [Internet]. 2021 [cited 2021 Sep 29]; Available from: https:\/\/beyoglueye.com\/jvi.aspx?un=BEJ-65487&volume=","DOI":"10.14744\/bej.2021.65487"},{"issue":"4","key":"1491_CR50","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1111\/aos.14014","volume":"97","author":"S Jandorf","year":"2019","unstructured":"Jandorf S, Krogh Nielsen M, S\u00f8rensen TL. Irrigating the eye after intravitreal injection reduces epithelial damage but not patient discomfort. Acta Ophthalmol 1755375X. 2019;97(4):e670-1.","journal-title":"Acta Ophthalmol 1755375X"},{"issue":"9","key":"1491_CR51","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1097\/IAE.0b013e3181dc04da","volume":"30","author":"DY Chong","year":"2010","unstructured":"Chong DY, Anand R, Williams PD, Qureshi JA, Callanan DG. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina. 2010;30(9):1432\u201340.","journal-title":"Retina"},{"key":"1491_CR52","doi-asserted-by":"crossref","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","DOI":"10.1056\/NEJMoa054481"},{"issue":"4","key":"1491_CR53","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1089\/jop.2015.0152","volume":"32","author":"AM Khanani","year":"2016","unstructured":"Khanani AM, Cohen GL, Zawadzki R. A prospective masked clinical assessment of inflammation after intravitreal injection of ranibizumab or aflibercept. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2016;32(4):216\u20138.","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther"},{"issue":"2","key":"1491_CR54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/09286586.2015.1090004","volume":"23","author":"EH Souied","year":"2016","unstructured":"Souied EH, Dugel PU, Ferreira A, Hashmonay R, Lu J, Kelly SP. Severe ocular inflammation following ranibizumab or aflibercept injections for age-related macular degeneration: a retrospective claims database analysis. Ophthalmic Epidemiol. 2016;23(2):71\u20139.","journal-title":"Ophthalmic Epidemiol"},{"issue":"10","key":"1491_CR55","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","volume":"127","author":"CR Baumal","year":"2020","unstructured":"Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127(10):1345\u201359.","journal-title":"Ophthalmology"},{"key":"1491_CR56","doi-asserted-by":"publisher","first-page":"943409","DOI":"10.1155\/2013\/943409","volume":"2013","author":"S Agrawal","year":"2013","unstructured":"Agrawal S, Joshi M, Christoforidis JB. Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators Inflamm. 2013;2013:943409.","journal-title":"Mediators Inflamm"},{"issue":"1","key":"1491_CR57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/sj.eye.6702938","volume":"23","author":"SJ Bakri","year":"2009","unstructured":"Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 2009;23(1):181\u20135.","journal-title":"Eye"},{"issue":"226","key":"1491_CR58","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ajo.2020.12.016","volume":"1","author":"SS Swaminathan","year":"2021","unstructured":"Swaminathan SS, Kunkler AL, Quan AV, Medert CM, Vanner EA, Feuer W, et al. Rates of RNFL thinning in patients with suspected or confirmed glaucoma receiving unilateral intravitreal injections for exudative AMD. Am J Ophthalmol. 2021;1(226):206\u201316.","journal-title":"Am J Ophthalmol"},{"key":"1491_CR59","doi-asserted-by":"crossref","unstructured":"Du J, Patrie JT, Prum BE, Netland PA, Shildkrot Y (Eugene). Effects of intravitreal anti-VEGF therapy on glaucoma-like progression in susceptible eyes. J Glaucoma. 2019;28(12):1035\u201340.","DOI":"10.1097\/IJG.0000000000001382"},{"issue":"10","key":"1491_CR60","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.oret.2020.03.028","volume":"4","author":"DA Mammo","year":"2020","unstructured":"Mammo DA, Ringeisen AL, Parke DW. Frequency of rhegmatogenous retinal detachment after intravitreal therapy in neovascular age-related macular degeneration. Ophthalmol Retina. 2020;4(10):973\u20138.","journal-title":"Ophthalmol Retina"},{"issue":"10","key":"1491_CR61","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.ophtha.2019.04.037","volume":"126","author":"PP Storey","year":"2019","unstructured":"Storey PP, Pancholy M, Wibbelsman TD, Obeid A, Su D, Borkar D, et al. Rhegmatogenous retinal detachment after intravitreal injection of anti\u2013vascular endothelial growth factor. Ophthalmology. 2019;126(10):1424\u201331.","journal-title":"Ophthalmology"},{"issue":"2","key":"1491_CR62","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/bjo.2007.127142","volume":"92","author":"JF Arevalo","year":"2008","unstructured":"Arevalo JF, Maia M, Flynn HW, Saravia M, Avery RL, Wu L, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"23","key":"1491_CR63","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1001\/jama.2020.23027","volume":"324","author":"AN Antoszyk","year":"2020","unstructured":"Antoszyk AN, Glassman AR, Beaulieu WT, Jampol LM, Jhaveri CD, Punjabi OS, et al. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy. JAMA. 2020;324(23):2383\u201395.","journal-title":"JAMA"},{"issue":"16","key":"1491_CR64","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/jnci\/djm086","volume":"99","author":"FA Scappaticci","year":"2007","unstructured":"Scappaticci FA, Skillings JR, Holden SN, Gerber H-P, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. JNCI J Natl Cancer Inst. 2007;99(16):1232\u20139.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"1","key":"1491_CR65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","volume":"134","author":"RL Avery","year":"2016","unstructured":"\u2022\u2022 Avery RL, Gordon GM. Systemic safety of prolonged monthly anti\u2013vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol. 2016;134(1):21\u20139. (This meta-analysis found an increased risk of death in patients that received monthly anti-VEGF injections over 2 years.)","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"1491_CR66","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.ophtha.2018.09.040","volume":"126","author":"MH Maloney","year":"2019","unstructured":"Maloney MH, Schilz SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of systemic adverse events associated with intravitreal anti\u2013VEGF therapy for diabetic macular edema in routine clinical practice. Ophthalmology. 2019;126(7):1007\u201315.","journal-title":"Ophthalmology"},{"issue":"5","key":"1491_CR67","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.3928\/23258160-20190503-14","volume":"50","author":"MR Starr","year":"2019","unstructured":"Starr MR, Dalvin LA, AbouChehade JE, Damento GM, Garcia MD, Shah SM, et al. Classification of strokes in patients receiving intravitreal anti-vascular endothelial growth factor. Ophthalmic Surg Lasers Imaging Retina. 2019;50(5):e140\u201357.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"3","key":"1491_CR68","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ophtha.2020.07.062","volume":"128","author":"MH Maloney","year":"2021","unstructured":"Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice. Ophthalmology. 2021;128(3):417\u201324.","journal-title":"Ophthalmology"},{"issue":"10","key":"1491_CR69","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","volume":"128","author":"LH Curtis","year":"2010","unstructured":"Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128(10):1273\u20139.","journal-title":"Arch Ophthalmol"},{"key":"1491_CR70","doi-asserted-by":"crossref","unstructured":"Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Eyes and Vision Group, editor. Cochrane Database Syst Rev [Internet]. 2018 Oct 16 [cited 2021 Aug 5]; Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD007419.pub6","DOI":"10.1002\/14651858.CD007419.pub6"},{"issue":"1","key":"1491_CR71","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ckj\/sfy060","volume":"12","author":"RM Hanna","year":"2018","unstructured":"Hanna RM, Lopez EA, Hasnain H, Selamet U, Wilson J, Youssef PN, et al. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J. 2018;12(1):92\u2013100.","journal-title":"Clin Kidney J"},{"issue":"2019","key":"1491_CR72","first-page":"e2919080","volume":"22","author":"F Touzani","year":"2019","unstructured":"Touzani F, Geers C, Pozdzik A. Intravitreal injection of anti-VEGF antibody induces glomerular endothelial cells injury. Case Rep Nephrol. 2019;22(2019):e2919080.","journal-title":"Case Rep Nephrol"},{"issue":"3","key":"1491_CR73","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.kint.2019.02.042","volume":"96","author":"RM Hanna","year":"2019","unstructured":"Hanna RM, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019;96(3):572\u201380.","journal-title":"Kidney Int"},{"issue":"3","key":"1491_CR74","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/ICB.0000000000000581","volume":"13","author":"GGB Meredith","year":"2019","unstructured":"Meredith GGB, Schkade PA, Joondeph BCM. Allergic reaction upon intravitreal administration of anti-vascular endothelial growth factor agents. Retin Cases Brief Rep Summer 2019. 2019;13(3):287\u20139.","journal-title":"Retin Cases Brief Rep Summer 2019"},{"issue":"21","key":"1491_CR75","doi-asserted-by":"publisher","first-page":"e6965","DOI":"10.1097\/MD.0000000000006965","volume":"96","author":"N Nagai","year":"2017","unstructured":"Nagai N, Ibuki M, Shinoda H, Kameyama K, Tsubota K, Ozawa Y. Maculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration: a case report. Medicine (Baltimore). 2017;96(21):e6965.","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"1491_CR76","doi-asserted-by":"crossref","first-page":"215265671876338","DOI":"10.1177\/2152656718763385","volume":"1","author":"RS Kleris","year":"2018","unstructured":"Kleris RS, Keswani A, Lugar P. The eyes have it: eyelid swelling and rash in a 79-year-old woman with macular degeneration. Allergy Rhinol. 2018;1(9):2152656718763385.","journal-title":"Allergy Rhinol"},{"issue":"5","key":"1491_CR77","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/14767050802645035","volume":"22","author":"G Galazios","year":"2009","unstructured":"Galazios G, Papazoglou D, Tsikouras P, Kolios G. Vascular endothelial growth factor gene polymorphisms and pregnancy. J Matern Fetal Neonatal Med. 2009;22(5):371\u20138.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"9","key":"1491_CR78","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.4239\/wjd.v12.i9.1386","volume":"12","author":"PP Choo","year":"2021","unstructured":"Choo PP, Md Din N, Azmi N, Bastion M-LC. Review of the management of sight-threatening diabetic retinopathy during pregnancy. World J Diabetes. 2021;12(9):1386\u2013400.","journal-title":"World J Diabetes"},{"issue":"10","key":"1491_CR79","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/humrep\/det308","volume":"28","author":"WY Almawi","year":"2013","unstructured":"Almawi WY, Saldanha FL, Mahmood NA, Al-Zaman I, Sater MS, Mustafa FE. Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage. Hum Reprod. 2013;28(10):2628\u201335.","journal-title":"Hum Reprod"},{"issue":"11","key":"1491_CR80","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1097\/IAE.0000000000002946","volume":"40","author":"PJ Dalal","year":"2020","unstructured":"Dalal PJ, Patel AL, Carle M, Rajanala A, Gill MK. Review of ophthalmic and breastfeeding medicine evidence: real and theoretical risks of intravitreal anti-vascular endothelial growth factor administration in lactating women. Retina. 2020;40(11):2065\u20139.","journal-title":"Retina"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-022-01491-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-022-01491-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-022-01491-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T09:02:19Z","timestamp":1700989339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-022-01491-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":80,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1491"],"URL":"https:\/\/doi.org\/10.1007\/s11892-022-01491-y","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"assertion":[{"value":"14 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}